Summit Therapeutics plc(SMMT)

Description: Summit Corporation plc, a drug discovery and development company, engages in the discovery and development of novel drug candidates to treat areas of high unmet medical need. The company licenses its drug discovery platform, known as Seglin technology, for the identification of new drug leads and candidates with the potential to target a range of diseases. Its pipeline consists of clinical stage programmes targeting Duchenne Muscular Dystrophy (DMD) and Clostridium difficile infection (CDI). The company provides SMT C1100, a small molecule Utrophin modulator for DMD patients that has completed Phase I clinical trial; and SMT 19969, a Phase I clinical trial completed novel molecule antibiotic for the treatment for initial CDI and prevention of recurrent disease. It is also engaged in other programmes that include OGA inhibitor programme for the treatment of dementia. The company has a technology license agreement with Bristol-Myers Squibb to access the Seglin technology platform. It has operations primarily in the United Kingdom and the United States. The company was formerly known as VASTox plc and changed its name to Summit Corporation Plc in July 2007. Summit Corporation plc was founded in 2003 and is headquartered in Abingdon, the United Kingdom.

---

Keywords: Medicine Disease Antibiotics Drug Discovery Dementia Summit Dystrophy Muscular Dystrophy Duchenne Muscular Dystrophy Duchenne Cdi Clostridioides Difficile Clostridium Difficile Infection Clostridium Difficile Drug Discovery Platform Ezutromid

---

Home Page: www.summittxinc.com

SMMT Technical Analysis

One Broadway
Cambridge, MA 02142
United States
Phone: 617 514 7149

---

Officers

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)